JP2005531580A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005531580A5 JP2005531580A5 JP2004507449A JP2004507449A JP2005531580A5 JP 2005531580 A5 JP2005531580 A5 JP 2005531580A5 JP 2004507449 A JP2004507449 A JP 2004507449A JP 2004507449 A JP2004507449 A JP 2004507449A JP 2005531580 A5 JP2005531580 A5 JP 2005531580A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- hydroxy
- cycloalkyl
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 38
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- 150000002431 hydrogen Chemical class 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000012453 solvate Substances 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- -1 nitro, hydroxy Chemical group 0.000 claims description 4
- PCVDRVDLJJWVCW-UHFFFAOYSA-N 7-(4-hydroxyphenyl)sulfonyl-2,3,4,5-tetrahydro-1h-3-benzazepin-8-ol Chemical compound C1=CC(O)=CC=C1S(=O)(=O)C(C(=C1)O)=CC2=C1CCNCC2 PCVDRVDLJJWVCW-UHFFFAOYSA-N 0.000 claims description 3
- RFUAYXROQMBXQN-UHFFFAOYSA-N 7-(benzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline Chemical compound C=1C=C2CCNCC2=CC=1S(=O)(=O)C1=CC=CC=C1 RFUAYXROQMBXQN-UHFFFAOYSA-N 0.000 claims description 2
- IGVZBVVFJNXNFL-UHFFFAOYSA-N 7-(benzenesulfonyl)-3-methyl-1,2,4,5-tetrahydro-3-benzazepin-8-ol Chemical compound C1=C2CCN(C)CCC2=CC(O)=C1S(=O)(=O)C1=CC=CC=C1 IGVZBVVFJNXNFL-UHFFFAOYSA-N 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 125000003107 substituted aryl group Chemical group 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 102000015554 Dopamine receptor Human genes 0.000 claims 2
- 108050004812 Dopamine receptor Proteins 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000000142 dyskinetic effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 201000009032 substance abuse Diseases 0.000 claims 2
- 231100000736 substance abuse Toxicity 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- BDINKTNMJQVETD-UHFFFAOYSA-N 1-sulfonyl-3,4-dihydro-2h-isoquinoline Chemical compound C1=CC=C2C(=S(=O)=O)NCCC2=C1 BDINKTNMJQVETD-UHFFFAOYSA-N 0.000 claims 1
- QJAOKOQONFKISX-UHFFFAOYSA-N 7-(4-butylphenyl)sulfonyl-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound C1=CC(CCCC)=CC=C1S(=O)(=O)C1=CC=C(CCNCC2)C2=C1 QJAOKOQONFKISX-UHFFFAOYSA-N 0.000 claims 1
- KYHQRXDLCZHFBF-UHFFFAOYSA-N 7-(4-butylphenyl)sulfonyl-3-methyl-1,2,4,5-tetrahydro-3-benzazepine Chemical compound C1=CC(CCCC)=CC=C1S(=O)(=O)C1=CC=C(CCN(C)CC2)C2=C1 KYHQRXDLCZHFBF-UHFFFAOYSA-N 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- YGLDQFWPUCURIP-UHFFFAOYSA-N 3h-3-benzazepine Chemical class C1=CNC=CC2=CC=CC=C21 YGLDQFWPUCURIP-UHFFFAOYSA-N 0.000 description 1
- UZZCRYZXXODAKU-UHFFFAOYSA-N 7-(benzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline;hydrochloride Chemical compound Cl.C=1C=C2CCNCC2=CC=1S(=O)(=O)C1=CC=CC=C1 UZZCRYZXXODAKU-UHFFFAOYSA-N 0.000 description 1
- 208000017228 Gastrointestinal motility disease Diseases 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0212399.0A GB0212399D0 (en) | 2002-05-29 | 2002-05-29 | Compounds |
| PCT/EP2003/005728 WO2003099792A1 (en) | 2002-05-29 | 2003-05-28 | 7-phenylsulfonyl-tetrahydro-3-benzazepine derivatives as antipsychotic agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005531580A JP2005531580A (ja) | 2005-10-20 |
| JP2005531580A5 true JP2005531580A5 (enExample) | 2006-07-13 |
Family
ID=9937658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004507449A Pending JP2005531580A (ja) | 2002-05-29 | 2003-05-28 | 抗精神病薬としての７−フェニルスルホニル−テトラヒドロ−３−ベンゾアゼピン誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20050245507A1 (enExample) |
| EP (1) | EP1509504A1 (enExample) |
| JP (1) | JP2005531580A (enExample) |
| AU (1) | AU2003273169A1 (enExample) |
| GB (1) | GB0212399D0 (enExample) |
| WO (1) | WO2003099792A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR040126A1 (es) | 2002-05-29 | 2005-03-16 | Glaxo Group Ltd | Compuesto de fenilsulfonilo, composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento |
| TW200510324A (en) * | 2003-08-11 | 2005-03-16 | Lilly Co Eli | 6-(2,2,2-trifluoroethylamino)-7-chiloro-2, 3, 4, 5-tetrahydro-1h-benzo[d]azepine as a 5-ht2c receptor agonist |
| CN102114244A (zh) * | 2004-09-30 | 2011-07-06 | 弗·哈夫曼-拉罗切有限公司 | 治疗认知障碍的组合物和方法 |
| US7713954B2 (en) | 2004-09-30 | 2010-05-11 | Roche Palo Alto Llc | Compositions and methods for treating cognitive disorders |
| EP1817037B1 (en) | 2004-12-02 | 2013-04-03 | Abbott GmbH & Co. KG | Triazole compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0285287A3 (en) * | 1987-03-23 | 1990-08-16 | Smithkline Beecham Corporation | 3-benzazepine compounds for use in treating gastrointestinal motility disorders |
| US5684195A (en) * | 1994-07-14 | 1997-11-04 | G. D. Searle & Co. | Method of preparing sulfmonamides from sulfones |
| GB9804734D0 (en) * | 1998-03-05 | 1998-04-29 | Pfizer Ltd | Compounds |
| DE10053799A1 (de) * | 2000-10-30 | 2002-05-08 | Bayer Ag | Verwendung von Tetrahydroisochinolinsulfonamiden |
| AU2303402A (en) * | 2000-11-14 | 2002-05-27 | Smithkline Beecham Plc | Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) |
-
2002
- 2002-05-29 GB GBGB0212399.0A patent/GB0212399D0/en not_active Ceased
-
2003
- 2003-05-28 EP EP03740167A patent/EP1509504A1/en not_active Withdrawn
- 2003-05-28 US US10/516,065 patent/US20050245507A1/en not_active Abandoned
- 2003-05-28 WO PCT/EP2003/005728 patent/WO2003099792A1/en not_active Ceased
- 2003-05-28 AU AU2003273169A patent/AU2003273169A1/en not_active Abandoned
- 2003-05-28 JP JP2004507449A patent/JP2005531580A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005518414A5 (enExample) | ||
| JP2009513703A5 (enExample) | ||
| JP2006505623A5 (enExample) | ||
| JP2010509356A5 (enExample) | ||
| JP2007520440A5 (enExample) | ||
| JP2013056930A5 (enExample) | ||
| JP2013525438A5 (enExample) | ||
| JP5337054B2 (ja) | ムスカリン受容体アンタゴニストとベータ−２−アドレナリン受容体アゴニストの組み合わせ | |
| JP2004532240A (ja) | ５−ｈｔ６受容体アンタゴニストとしてのベンゾ［ｄ］アゼピン誘導体 | |
| ES2277098T3 (es) | Derivados de quinolina y aza-indol y su uso como ligandos para 5-ht6. | |
| JP2005509622A5 (enExample) | ||
| AU2015335783B2 (en) | Tricyclic atropisomer compounds | |
| JP2006507220A5 (enExample) | ||
| JP2006523193A5 (enExample) | ||
| JP2004532240A5 (enExample) | ||
| JP2011517443A5 (enExample) | ||
| JP2005522452A5 (enExample) | ||
| JP2005527542A5 (enExample) | ||
| JP2006523192A5 (enExample) | ||
| JP2010506919A5 (enExample) | ||
| JP2009512635A5 (enExample) | ||
| JP2005508969A5 (enExample) | ||
| JP2005531580A5 (enExample) | ||
| JP2007503432A5 (enExample) | ||
| JP2007532628A5 (enExample) |